Related Experiment Video
Updated: Jul 29, 2026
08:04
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
11.7K
Dexamethasone potentiates chimeric antigen receptor T cell persistence and function by enhancing IL-7Rα expression
Ashlie M Munoz1, Ryan Urak1, Ellie Taus1
1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA 91010, USA.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|December 23, 2023
Summary
Dexamethasone (dex) does not inhibit CAR T-cell function. This study shows dex enhances CAR T-cell persistence and tumor regression, offering new strategies for cancer immunotherapy.
Area of Science:
- Immunology
- Cell Biology
- Oncology
Background:
- Dexamethasone (dex) is a glucocorticoid used for inflammatory conditions, including immunotherapy toxicities.
- The effect of dex on Chimeric Antigen Receptor (CAR) T-cell activity remains unclear.
- CAR T-cell therapy is a promising cancer treatment.
Purpose of the Study:
- To investigate the impact of dexamethasone on CAR T-cell phenotype and function.
- To explore dexamethasone as an adjuvant therapy to enhance CAR T-cell efficacy.
- To identify mechanisms by which dexamethasone may affect CAR T-cells.
Main Methods:
- CAR T-cells were treated with dexamethasone ex vivo and in vivo.
- Phenotypic analysis and functional assays were performed on CAR T-cells.
- Gene expression analysis was conducted to identify affected pathways.
- Tumor-bearing mice models were used to assess in vivo efficacy.
Main Results:
- Dexamethasone did not inhibit CAR T-cell expansion or function across various CAR constructs and tumor models.
- Dex upregulated interleukin-7 receptor alpha (IL-7Rα) on CAR T-cells.
- Dex enhanced the expression of genes related to CAR T-cell activation, migration, and persistence.
- Combined dexamethasone and IL-7 administration increased CAR T-cell persistence and led to complete tumor regression in mice.
Conclusions:
- Dexamethasone can be safely used with CAR T-cells without compromising their function.
- Dexamethasone enhances CAR T-cell persistence and anti-tumor activity.
- This research suggests novel strategies for improving CAR T-cell therapy production and clinical application.
